# OnCo record selumetinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/selumetinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "selumetinib" ;
  schema:name "Selumetinib"@en ;
  schema:description "Selumetinib (Koselugo) is the first medicine for children and adults with neurofibromatosis type 1 whose plexiform neurofibromas, benign but disfiguring and painful nerve tumours, cannot be removed by surgery."@en ;
  schema:url <https://onco.cc/drugs/selumetinib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Selumetinib> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=selumetinib>, <https://www.cancer.gov/about-cancer/treatment/drugs/selumetinibsulfate>, <https://www.ema.europa.eu/en/medicines/human/EPAR/koselugo> ;
  onco:status "approved" ;
  onco:tag "nci-list" ;
  onco:modality "Small-molecule allosteric MEK1/2 inhibitor" ;
  schema:alternateName "Koselugo" ;
  onco:approval "US 2020: NF1 with symptomatic, inoperable plexiform neurofibromas, children 2 and over (extended to adults and to age 1 and over in 2025)", "EU 2021: Symptomatic, inoperable plexiform neurofibromas in NF1, children 3 and over (conditional)" ;
  onco:related <https://onco.cc/drugs/trametinib/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/mek/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/merck/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:trials <https://onco.cc/trials/nct01933932/> .